Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soleno Therapeutics, Inc. - Common Stock (NQ:SLNO)

68.56 +0.89 (+1.32%)
Streaming Delayed Price Updated: 2:27 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,320,141
Open 67.54
Bid (Size) 68.05 (3)
Ask (Size) 68.71 (2)
Prev. Close 67.67
Today's Range 65.39 - 72.88
52wk Range 41.50 - 90.32
Shares Outstanding 8,168,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire

Performance

YTD
+50.0%
+50.0%
1 Month
+34.0%
+34.0%
3 Month
-19.8%
-19.8%
6 Month
-2.0%
-2.0%
1 Year
+26.6%
+26.6%

More News

Read More
SOLENO (SLNO) REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Soleno Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
SOLENO INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
From Pomerantz LLP
Via GlobeNewswire
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short
Via Benzinga
Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
From Pomerantz LLP
Via GlobeNewswire
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Soleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
From Gibbs Mura
Via Business Wire
SLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Soleno Therapeutics Stock Tanks After Patient Treated With Drug Dies – More Details Inside
Via Stocktwits
Topics Death
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
From Pomerantz LLP
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Fortinet, Roblox, Soleno, and Simulations Plus and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Soleno Therapeutics, Inc. - Common Stock publicly traded?
Yes, Soleno Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Soleno Therapeutics, Inc. - Common Stock trade on?
Soleno Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Soleno Therapeutics, Inc. - Common Stock?
The ticker symbol for Soleno Therapeutics, Inc. - Common Stock is SLNO on the Nasdaq Stock Market
What is the current price of Soleno Therapeutics, Inc. - Common Stock?
The current price of Soleno Therapeutics, Inc. - Common Stock is 68.56
When was Soleno Therapeutics, Inc. - Common Stock last traded?
The last trade of Soleno Therapeutics, Inc. - Common Stock was at 10/16/25 02:27 PM ET
What is the market capitalization of Soleno Therapeutics, Inc. - Common Stock?
The market capitalization of Soleno Therapeutics, Inc. - Common Stock is 560.09M
How many shares of Soleno Therapeutics, Inc. - Common Stock are outstanding?
Soleno Therapeutics, Inc. - Common Stock has 560M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.